✦ LIBER ✦

42 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody removab® (anti-CD3 X anti-EpCAM)

✍ Scribed by A. Burges; P. Wimberger; V.A. Gorbounova; H. Sommer; B. Schmalfeldt; J. Pfisterer; M. Ströhlein; M.R. Lichinitser; A.N. Makhson; R. Kimmig

Book ID: 118620218
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 164 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90076-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-974 Treatment of non-small cell lung c

P-974 Treatment of non-small cell lung cancer (NSCLC) patients withthe trifunctional bispecific antibody catumaxomab (removab®) (anti-EpCAM × anti-CD3: Results of a phase I study

✍ Sebastian, M.; Schmittel, A.; Friccius-Quecke, H.; Kanniess, F.; Wiewrodt, R.; L 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 140 KB

659 POSTER Intraperitoneal application o

659 POSTER Intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3) for the treatment of peritoneal carcinomatosis due to GI cancer: Results of a phase I trial

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 279 KB

5005 ORAL Randomized, multicenter, 2-dos

5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

✍ Loibl, S.; Pfisterer, J.; Wimberger, P.; Kurzeder, C.; Du Bois, A.; Sehouli, J.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 59 KB